The basic biology and immunobiology of renal cell carcinoma: considerations for the clinician.
These are indeed exciting times in the study of RCC. No longer should the clinician view RCC as a single entity, nor should the researcher pose basic questions without considering the biologic diversity of this tumor. The success of novel targeted therapeutic strategies will depend on the systematic study of genetic and epigenetic events and their relationship to aberrant protein expression and function, and an understanding of the permissive microenvironment that allows the tumor to be sustained. These studies must be correlated in a rigorous fashion to clinical parameters and outcomes. Progress against this elusive tumor will require a continuous translational dialogue between laboratory and clinical investigators.
Uzzo
Robert G
RG
Department of Surgical Oncology, Division of Urology, Fox Chase Cancer Center, Temple University School of Medicine, 7701 Burholme Avenue, Room C308, Philadelphia, PA 19111, USA. R_Uzzo@fccc.edu
Cairns
Paul
P
Al-Saleem
Tahseen
T
Hudes
Gary
G
Haas
Naomi
N
Greenberg
Richard E
RE
Kolenko
Vladimir
V
D002292:Carcinoma, Renal Cell / Q000235:genetics* / Q000276:immunology*; D006801:Humans; D007680:Kidney Neoplasms / Q000235:genetics* / Q000276:immunology*